1. WHO Classification of Skin Tumours, 4th edn; 2018.

2. Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T: Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol 2017, 177(2): 359 - 372.

3. Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988, 124(6): 869 - 871.

4. Rosso S, Zanetti R, Martinez C, Tormo MJ, Schraub S, Sancho-Garnier H, Franceschi S, Gafa L, Perea E, Navarro C et al: The multicentre south European study "Helios". II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996, 73(11): 1447 - 1454.

5. Leffell DJ, Carucci JA: Management of Skin Cancer. In: Cancer: Principles and Practice of Oncology. 6th edn. Edited by Devita VT, Hellman S, Rosenberg SA: Lippincott Williams & Wilkins.

6. Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS: Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol 2014, 134(1): 213 - 220.

7. Reifenberger J, Wolter M, Knobbe CB, Kohler B, Schonicke A, Scharwachter C, Kumar K, Blaschke B, Ruzicka T, Reifenberger G: Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005, 152(1): 43 - 51.

8. Lam C, Ou JC, Billingsley EM: "PTCH"-ing it together: a basal cell nevus syndrome review. Dermatol Surg 2013, 39(11): 1557 - 1572.

9. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, Coldiron BM: Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010, 146(3): 283 - 287.

10. Lomas A, Leonardi-Bee J, Bath-Hextall F: A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012, 166(5): 1069 - 1080.

11. Rubin AI, Chen EH, Ratner D: Basal-cell carcinoma. N Engl J Med 2005, 353(21): 2262 - 2269.

12. Kuo KY, Batra P, Cho HG, Li S, Chahal HS, Rieger KE, Tang JY, Sarin KY: Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution. J Am Acad Dermatol 2017, 77(2): 233 - 234 e232.

13. Каприн АД, Старинский ВВ, Петрова ГВ (eds.): Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2019.

14. Каприн АД, Старинский ВВ, Петрова ГВ (eds.): Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2019.

15. Каприн АД, Старинский ВВ, Петрова ГВ (eds.): Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2018.

16. Zou Y, Zhao Y, Yu J, Luo X, Han J, Ye Z, Li J, Lin H: Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. J Cosmet Dermatol 2016, 15(4): 374 - 382.

17. Каприн АД, Старинский ВВ, Петрова ГВ (eds.): Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2018.

18. Brierley JD, Gospodarowicz MK, Wittekind C (eds.): TNM classification of malignant tumors, 8th edn. Oxford, UK: John Wiley & Sons, Inc; 2017.

19. Bichakjian C, Aasi SZ, Alam M, Andersen JS, Blitzblau R, Bordeaux J, Bowen GM, Chen PL, Contreras CM, Mackenzie D et al: Basal cell skin cancer. NCCN clinical practice guidelines in oncology. Version 1.2019 - August 31.2018. 2019:46.

20. Badash I, Shauly O, Lui CG, Gould DJ, Patel KM: Nonmelanoma Facial Skin Cancer: A Review of Diagnostic Strategies, Surgical Treatment, and Reconstructive Techniques. Clin Med Insights Ear Nose Throat 2019, 12:1179550619865278.

21. Marzuka AG, Book SE: Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 2015, 88(2): 167 - 179.

22. Renzi M, Jr., Schimmel J, Decker A, Lawrence N: Management of Skin Cancer in the Elderly. Dermatol Clin 2019, 37(3): 279 - 286.

23. Tanese K: Diagnosis and Management of Basal Cell Carcinoma. Curr Treat Options Oncol 2019, 20(2):13.

24. Reggiani C, Zalaudek I, Piana S, Longo C, Argenziano G, Lallas A, Pellacani G, Moscarella E: Fibroepithelioma of Pinkus: case reports and review of the literature. Dermatology 2013, 226(3): 207 - 211.

25. Moreira C, Morais P, Santos P, Castro M, Azevedo F: Phenotypic spectrum of a patient with Gorlin"s syndrome and role of dermoscopy in the early detection of basal cell carcinomas. An Bras Dermatol 2015, 90(3): 416 - 419.

26. Bajdik CD, Gallagher RP, Astrakianakis G, Hill GB, Fincham S, McLean DI: Non-solar ultraviolet radiation and the risk of basal and squamous cell skin cancer. Br J Cancer 1996, 73(12): 1612 - 1614.

27. Srinivas N, Rachakonda S, Hielscher T, Calderazzo S, Rudnai P, Gurzau E, Koppova K, Fletcher T, Kumar R: Telomere length, arsenic exposure and risk of basal cell carcinoma of skin. Carcinogenesis 2019, 40(6): 715 - 723.

28. deShazo R, Soltani-Arabshahi R, Krishnasamy S, Langley RG, Kalia S, Stahle M, Langholff W, Goyal K, Fakharzadeh S, Galindo C et al: Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol 2019, 18(10): 1059 - 1060.

29. Elnahas S, Olson MT, Kang P, Panchanathan R, Masuda T, Walia R, Zeitouni NC, Smith MA, Bremner RM: Factors associated with skin cancer in lung transplant recipients: A single-center experience. Clin Transplant 2019:e13718.

30. Huang JT, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Al-Sayegh H, London WB, Marghoob A et al: Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. J Pediatr 2019, 211: 152 - 158.

31. Oliveira WRP, Tirico M, Souza AAV, Codarin FR, Silva LLC, Festa Neto C: Skin lesions in organ transplant recipients: a study of 177 consecutive Brazilian patients. Int J Dermatol 2019, 58(4): 440 - 448.

32. Oh CC, Lee HY, Tan BK, Assam PN, Kee TYS, Pang SM: Dermatological conditions seen in renal transplant recipients in a Singapore tertiary hospital. Singapore Med J 2018, 59(10): 519 - 523.

33. Collins L, Quinn A, Stasko T: Skin Cancer and Immunosuppression. Dermatol Clin 2019, 37(1): 83 - 94.

34. Lee CT, Lehrer EJ, Aphale A, Lango M, Galloway TJ, Zaorsky NG: Surgical excision, Mohs micrographic surgery, external-beam radiotherapy, or brachytherapy for indolent skin cancer: An international meta-analysis of 58 studies with 21,000 patients. Cancer 2019, 125(20): 3582 - 3594.

35. Martinez MF, Mazzuoccolo LD, Oddo EM, Iscoff PV, Muchnik C, Neumann HPH, Martin RS, Fraga AR, Azurmendi PJ: Co-Inheritance of Autosomal Dominant Polycystic Kidney Disease and Naevoid Basal Cell Carcinoma Syndrome: Effects on Renal Progression. Nephron 2018, 140(4): 282 - 288.

36. Dinnes J, Deeks JJ, Grainge MJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, Wong KY, Aldridge RB, Abbott R et al: Visual inspection for diagnosing cutaneous melanoma in adults. Cochrane Database of Systematic Reviews 2018(12).

37. Grange F: [Multiple primary melanoma and familial melanoma. Risk evaluation and screening tests. How to evaluate the risk of developing a second melanoma? In what family? Should screening methods be implemented? Which ones and why?]. Ann Dermatol Venereol 1995, 122(5): 365 - 371.

38. Claeson M, Holmstrom P, Hallberg S, Gillstedt M, Gonzalez H, Wennberg AM, Paoli J: Multiple Primary Melanomas: A Common Occurrence in Western Sweden. Acta Derm Venereol 2016.

39. Moore MM, Geller AC, Warton EM, Schwalbe J, Asgari MM: Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011. J Am Acad Dermatol 2015, 73(4): 630 - 636.

40. Dinnes J, Deeks JJ, Chuchu N, Matin RN, Wong KY, Aldridge RB, Durack A, Gulati A, Chan SA, Johnston L et al: Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults. Cochrane Database Syst Rev 2018, 12:CD011901.

41. Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Ebell M, Epling JW, Jr., Garcia FA, Gillman MW, Kemper AR et al: Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2016, 316(4): 429 - 435.

42. Reiter O, Mimouni I, Gdalevich M, Marghoob AA, Levi A, Hodak E, Leshem YA: The diagnostic accuracy of dermoscopy for basal cell carcinoma: A systematic review and meta-analysis. J Am Acad Dermatol 2019, 80(5): 1380 - 1388.

43. Gassenmaier M, Stec T, Keim U, Leiter U, Eigentler TK, Metzler G, Garbe C: Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry. J Eur Acad Dermatol Venereol 2019, 33(1): 63 - 70.

44. Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Blasi PR: Screening for Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016, 316(4): 436 - 447.

45. Zalaudek I, Ferrara G, Broganelli P, Moscarella E, Mordente I, Giacomel J, Argenziano G: Dermoscopy patterns of fibroepithelioma of pinkus. Arch Dermatol 2006, 142(10): 1318 - 1322.

46. Giacomel J, Lallas A, Argenziano G, Reggiani C, Piana S, Apalla Z, Ferrara G, Moscarella E, Longo C, Zalaudek I: Dermoscopy of basosquamous carcinoma. Br J Dermatol 2013, 169(2): 358 - 364.

47. Lallas A, Tzellos T, Kyrgidis A, Apalla Z, Zalaudek I, Karatolias A, Ferrara G, Piana S, Longo C, Moscarella E et al: Accuracy of dermoscopic criteria for discriminating superficial from other subtypes of basal cell carcinoma. J Am Acad Dermatol 2014, 70(2): 303 - 311.

48. Kiladze N, Shulaia T, Bulinska A, Abrahamovych L: Dermatoscopic features of pigmented and non-pigmented basal cell carcinoma. Georgian Med News 2015(238): 50 - 53.

49. Lallas A, Apalla Z, Ioannides D, Argenziano G, Castagnetti F, Moscarella E, Longo C, Palmieri T, Ramundo D, Zalaudek I: Dermoscopy in the diagnosis and management of basal cell carcinoma. Future Oncol 2015, 11(22): 2975 - 2984.

50. Lallas A, Argenziano G, Ioannides D: Dermoscopy for basal cell carcinoma subtype prediction. Br J Dermatol 2016, 175(4): 674 - 675.

51. Reiter O, Mimouni I, Dusza S, Halpern AC, Leshem YA, Marghoob AA: Dermoscopic Features of Basal Cell Carcinoma and its Subtypes: A systematic Review. J Am Acad Dermatol 2019.

52. Ferrante di Ruffano L, Dinnes J, Chuchu N, Bayliss SE, Takwoingi Y, Davenport C, Matin RN, O"Sullivan C, Roskell D, Deeks JJ et al: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. Cochrane Database Syst Rev 2018, 12: CD013187.

53. Бровкина АФ: Офтальмоонкология. Москва: Медицина; 2002.

54. Бровкина АФ, Панова ИЕ, Саакян СВ: Офтальмоонкология: новое за последние два десятилетия. Вестник офтальмологии 2014, 130(6): 13 - 19.

55. Вальский ВВ, Бородин ЮИ, Саакян СВ: Эффективность протонотерапии эпителиальных злокачественных опухолей придаточного аппарата глаза редуцированной суммарной очаговой дозой. Опухоли головы и шеи 2016, 1(6): 47 - 48.

56. Важенина ДА, Васильев СА, Дудник СН: Рецидивирующий базальноклеточный рак кожи век (особенности клинического течения, лечения). Российский медицинский журнал 2016, 11: 36 - 43.

57. Енгибарян МА, Пустовая ИВ, Ульянова ЮВ: Первичная аутопластика в хирургическом лечении опухолей внутреннего угла глаза. Известия ВУЗ Северо-Кавказский Регион Естественные Науки 2011: 34 - 36.

58. Панова ИЕ, Васильев СА, Семенов ЛЕ: Рецидивирующий базальноклеточный рак кожи век. Клиническая офтальмология 2006, 7(1): 11 - 14.

59. Kadouch DJ, Leeflang MM, Elshot YS, Longo C, Ulrich M, van der Wal AC, Wolkerstorfer A, Bekkenk MW, de Rie MA: Diagnostic accuracy of confocal microscopy imaging vs. punch biopsy for diagnosing and subtyping basal cell carcinoma. J Eur Acad Dermatol Venereol 2017, 31(10): 1641 - 1648.

60. Buchwald HJ, Muller A, Kampmeier J, Lang GK: [Optical coherence tomography versus ultrasound biomicroscopy of conjunctival and eyelid lesions]. Klin Monbl Augenheilkd 2003, 220(12): 822 - 829.

61. Crowson AN: Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006, 19 Suppl 2: S127 - 147.

62. Husein-ElAhmed H, Fernandez-Pugnaire MA: Dermatoscopy-guided therapy of pigmented basal cell carcinoma with imiquimod. An Bras Dermatol 2016, 91(6): 764 - 769.

63. Lallas A, Argenziano G, Zendri E, Moscarella E, Longo C, Grenzi L, Pellacani G, Zalaudek I: Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. Expert Rev Anticancer Ther 2013, 13(5): 541 - 558.

64. Bath-Hextall FJ, Perkins W, Bong J, Williams HC: Interventions for basal cell carcinoma of the skin. Cochrane Database of Systematic Reviews 2007.

65. Rowe DE, Carroll RJ, Day CL, Jr.: Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989, 15(3): 315 - 328.

66. Rowe DE, Carroll RJ, Day CL, Jr.: Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989, 15(4): 424 - 431.

67. Avril MF, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E, Guillaume JC, Chalon R, Petit JY, Sancho-Garnier H et al: Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997, 76(1): 100 - 106.

68. Petit JY, Avril MF, Margulis A, Chassagne D, Gerbaulet A, Duvillard P, Auperin A, Rietjens M: Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg 2000, 105(7): 2544 - 2551.

69. Thissen MR, Nieman FH, Ideler AH, Berretty PJ, Neumann HA: Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000, 26(8): 759 - 764.

70. Kuijpers DI, Thissen MR, Berretty PJ, Ideler FH, Nelemans PJ, Neumann MH: Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg 2007, 33(5): 579 - 587.

71. Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, Williams HC, Surgery versus Imiquimod for Nodular Superficial basal cell carcinoma study g: Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 2014, 15(1): 96 - 105.

72. Bozan A, Gode S, Kaya I, Yaman B, Uslu M, Akyildiz S, Apaydin F, Ceylan C, Ozturk G: Long-term Follow-up of Positive Surgical Margins in Basal Cell Carcinoma of the Face. Dermatol Surg 2015, 41(7): 761 - 767.

73. Newlands C, Currie R, Memon A, Whitaker S, Woolford T: Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016, 130(S2): S125 - S132.

74. Fukumoto T, Fukumoto R, Oka M, Horita N: Comparing Treatments for Basal Cell Carcinoma in Terms of Long-term Treatment-Failure: A Network Meta-analysis. J Eur Acad Dermatol Venereol 2019.

75. Gulleth Y, Goldberg N, Silverman RP, Gastman BR: What is the best surgical margin for a Basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg 2010, 126(4): 1222 - 1231.

76. Wolf DJ, Zitelli JA: Surgical margins for basal cell carcinoma. Arch Dermatol 1987, 123(3): 340 - 344.

77. Phan K, Oh LJ, Goyal S, Rutherford T, Yazdabadi A: Recurrence rates following surgical excision of periocular basal cell carcinomas: systematic review and meta-analysis. J Dermatolog Treat 2019: 1 - 5.

78. American Academy of D, American College of Mohs S, American Society for Dermatologic Surgery A, American Society for Mohs S, Ad Hoc Task F, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA et al: AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. Dermatol Surg 2012, 38(10): 1582 - 1603.

79. Barlow JO, Zalla MJ, Kyle A, DiCaudo DJ, Lim KK, Yiannias JA: Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol 2006, 54(6): 1039 - 1045.

80. Blixt E, Nelsen D, Stratman E: Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone. Dermatol Surg 2013, 39(5): 719 - 725.

81. Julian C, Bowers PW, Pritchard C: A comparative study of the effects of disposable and Volkmann spoon curettes in the treatment of basal cell carcinoma. Br J Dermatol 2009, 161(6): 1407 - 1409.

82. Rodriguez-Vigil T, Vazquez-Lopez F, Perez-Oliva N: Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol 2007, 56(1): 91 - 95.

83. Drucker AM, Adam GP, Rofeberg V, Gazula A, Smith B, Moustafa F, Weinstock MA, Trikalinos TA: Treatments of Primary Basal Cell Carcinoma of the Skin: A Systematic Review and Network Meta-analysis. Ann Intern Med 2018, 169(7): 456 - 466.

84. Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP: Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope 2009, 119(10): 1994 - 1999.

85. Hernandez-Machin B, Borrego L, Gil-Garcia M, Hernandez BH: Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. Int J Dermatol 2007, 46(5): 453 - 459.

86. Veness MJ, Delishaj D, Barnes EA, Bezugly A, Rembielak A: Current Role of Radiotherapy in Non-melanoma Skin Cancer. Clin Oncol (R Coll Radiol) 2019, 31(11): 749 - 758.

87. Hauschild A, Breuninger H, Kaufmann R, Kortmann RD, Klein M, Werner J, Reifenberger J, Dirschka T, Garbe C: Brief S2k guidelines - Basal cell carcinoma of the skin. J Dtsch Dermatol Ges 2013, 11 Suppl 3: 10 - 15, 11 - 16.

88. Rishi A, Hui Huang S, O'Sullivan B, Goldstein DP, Lu L, Ringash J, Waldron J, Wells W, Sun A, Hope A et al: Outcome following radiotherapy for head and neck basal cell carcinoma with "aggressive" features. Oral Oncol 2017, 72: 157 - 164.

89. Likhacheva A, Awan M, Barker CA, Bhatnagar A, Bradfield L, Brady MS, Buzurovic I, Geiger JL, Parvathaneni U, Zaky S et al: Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol 2019.

90. Khan L, Choo R, Breen D, Assaad D, Fialkov J, Antonyshyn O, McKenzie D, Woo T, Zhang L, Barnes E: Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. Radiother Oncol 2012, 104(2): 263 - 266.

91. Grossi Marconi D, da Costa Resende B, Rauber E, de Cassia Soares P, Fernandes JMJ, Mehta N, Lopes Carvalho A, Kupelian PA, Chen A: Head and Neck Non-Melanoma Skin Cancer Treated By Superficial X-Ray Therapy: An Analysis of 1021 Cases. PLoS One 2016, 11(7): e0156544.

92. van Hezewijk M, Creutzberg CL, Putter H, Chin A, Schneider I, Hoogeveen M, Willemze R, Marijnen CA: Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. Radiother Oncol 2010, 95(2): 245 - 249.

93. Duinkerken CW, Lohuis P, Crijns MB, Navran A, Haas RLM, Hamming-Vrieze O, Klop WMC, van den Brekel MWM, Al-Mamgani A: Orthovoltage X-rays for Postoperative Treatment of Resected Basal Cell Carcinoma in the Head and Neck Area. J Cutan Med Surg 2017, 21(3): 243 - 249.

94. Jeannon JP, Riddle PJ, Irish J, O'Sullivan B, Brown DH, Gullane P: Prognostic indicators in carcinoma of the nasal vestibule. Clin Otolaryngol 2007, 32(1): 19 - 23.

95. Olschewski T, Bajor K, Lang B, Lang E, Seegenschmiedt MH: [Radiotherapy of basal cell carcinoma of the face and head: Importance of low dose per fraction on long-term outcome]. J Dtsch Dermatol Ges 2006, 4(2): 124 - 130.

96. Dundar Y, Cannon RB, Hunt JP, Monroe M, Suneja G, Hitchcock YJ: Radiotherapy regimens in patients with nonmelanoma head and neck skin cancers. Int J Dermatol 2018, 57(4): 441 - 448.

97. Ferro M, Deodato F, Macchia G, Gentileschi S, Cilla S, Torre G, Padula GD, Nuzzo M, Massaccesi M, Valentini V et al: Short-course radiotherapy in elderly patients with early stage non-melanoma skin cancer: a phase II study. Cancer Invest 2015, 33(2): 34 - 38.

98. Gunaratne DA, Veness MJ: Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: Results of a systematic review. J Med Imaging Radiat Oncol 2018, 62(3): 401 - 411.

99. Lancellotta V, Kovacs G, Tagliaferri L, Perrucci E, Colloca G, Valentini V, Aristei C: Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer. Biomed Res Int 2018, 2018: 2178469.

100. Belaid A, Nasr C, Benna M, Cherif A, Jmour O, Bouguila H, Benna F: Radiation Therapy for Primary Eyelid Cancers in Tunisia. Asian Pac J Cancer Prev 2016, 17(7): 3643 - 3646.

101. Lancellotta V, Kovacs G, Tagliaferri L, Perrucci E, Rembielak A, Stingeni L, Tramontana M, Hansel K, Colloca G, Saldi S et al: The role of personalized Interventional Radiotherapy (brachytherapy) in the management of older patients with non-melanoma skin cancer. J Geriatr Oncol 2019, 10(3): 514 - 517.

102. Jumeau R, Renard-Oldrini S, Courrech F, Buchheit I, Oldrini G, Vogin G, Peiffert D: High dose rate brachytherapy with customized applicators for malignant facial skin lesions. Cancer Radiother 2016, 20(5): 341 - 346.

103. Guinot JL, Rembielak A, Perez-Calatayud J, Rodriguez-Villalba S, Skowronek J, Tagliaferri L, Guix B, Gonzalez-Perez V, Valentini V, Kovacs G et al: GEC-ESTRO ACROP recommendations in skin brachytherapy. Radiother Oncol 2018, 126(3): 377 - 385.

104. Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH: Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol 2012, 67(6): 1235 - 1241.

105. Паньшин ГА, Рыбаков ЮН, Близнюков ОП: Лучевая терапия базальноклеточного рака кожи с использованием близкофокусной рентгентерапии и электонного излучения с энергией 6 - 12 МэВ. Вестник РНЦРР 2015, 15.

106. Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P: Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol 1986, 37(1): 33 - 34.

107. Wang I, Bendsoe N, Klinteberg CA, Enejder AM, Andersson-Engels S, Svanberg S, Svanberg K: Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001, 144(4): 832 - 840.

108. Basset-Seguin N, Ibbotson SH, Emtestam L, Tarstedt M, Morton C, Maroti M, Calzavara-Pinton P, Varma S, Roelandts R, Wolf P: Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008, 18(5): 547 - 553.

109. Kuflik EG: Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg 2004, 30(2 Pt 2): 297 - 300.

110. Samain A, Boullie MC, Duval-Modeste AB, Joly P: Cryosurgery and curettage-cryosurgery for basal cell carcinomas of the mid-face. J Eur Acad Dermatol Venereol 2015, 29(7): 1291 - 1296.

111. Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, Wong GA, Richard MA, Anstey A, Wolf P: Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007, 143(9): 1131 - 1136.

112. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA, International Society for Photodynamic Therapy in D: Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007, 56(1): 125 - 143.

113. Kuijpers DI, Thissen MR, Thissen CA, Neumann MH: Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol 2006, 5(7): 642 - 645.

114. Savoia P, Deboli T, Previgliano A, Broganelli P: Usefulness of Photodynamic Therapy as a Possible Therapeutic Alternative in the Treatment of Basal Cell Carcinoma. Int J Mol Sci 2015, 16(10): 23300 - 23317.

115. Berroeta L, Clark C, Dawe RS, Ibbotson SH, Fleming CJ: A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. Br J Dermatol 2007, 157(2): 401 - 403.

116. Szeimies RM, Ibbotson S, Murrell DF, Rubel D, Frambach Y, de Berker D, Dummer R, Kerrouche N, Villemagne H, Excilight Study G: A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8 - 20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008, 22(11): 1302 - 1311.

117. Roozeboom MH, Aardoom MA, Nelemans PJ, Thissen MR, Kelleners-Smeets NW, Kuijpers DI, Mosterd K: Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol 2013, 69(2): 280 - 287.

118. Cosgarea R, Susan M, Crisan M, Senila S: Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol Venereol 2013, 27(8): 980 - 984.

119. Wang H, Xu Y, Shi J, Gao X, Geng L: Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed 2015, 31(1): 44 - 53.

120. Roozeboom MH, Nelemans PJ, Mosterd K, Steijlen PM, Arits AH, Kelleners-Smeets NW: Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial. Br J Dermatol 2015, 172(3): 739 - 745.

121. Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW: Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol 2012, 167(4): 733 - 756.

122. Jerjes W, Hamdoon Z, Hopper C: Photodynamic therapy in the management of basal cell carcinoma: Retrospective evaluation of outcome. Photodiagnosis Photodyn Ther 2017, 19: 22 - 27.

123. Buzza HH, Moriyama LT, Vollet-Filho JD, Inada NM, da Silva AP, Stringasci MD, Requena MB, de Andrade CT, Blanco KC, Ramirez DP et al: Overall Results for a National Program of Photodynamic Therapy for Basal Cell Carcinoma: A Multicenter Clinical Study to Bring New Techniques to Social Health Care. Cancer Control 2019, 26(1):1073274819856885.

124. Церковский ДА, Мазуренко АН, Петровская НА, Артемьева ТП: Фотодинамическая терапия базальноклеточного рака кожи с фотосенсибилизатором фотолон. Biomedical Photonics 2017, 6(1): 12 - 19.

125. Chan AL, Juarez M, Allen R, Volz W, Albertson T: Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces. Photodermatol Photoimmunol Photomed 2005, 21(2): 72 - 78.

126. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004, 50(5): 722 - 733.

127. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia Diez A, Tebbs V, McRae S: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005, 152(5): 939 - 947.

128. Quirk C, Gebauer K, De"Ambrosis B, Slade HB, Meng TC: Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis 2010, 85(6): 318 - 324.

129. Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, van Pelt HP, Quaedvlieg PJ, Krekels GA, van Neer PA et al: Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013, 14(7): 647 - 654.

130. Jansen MHE, Mosterd K, Arits A, Roozeboom MH, Sommer A, Essers BAB, van Pelt HPA, Quaedvlieg PJF, Steijlen PM, Nelemans PJ et al: Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma. J Invest Dermatol 2018, 138(3): 527 - 533.

131. van Loo E, Mosterd K, Krekels GA, Roozeboom MH, Ostertag JU, Dirksen CD, Steijlen PM, Neumann HA, Nelemans PJ, Kelleners-Smeets NW: Surgical excision versus Mohs" micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. Eur J Cancer 2014, 50(17): 3011 - 3020.

132. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, Steijlen PM, Vermeulen A, Neumann H, Kelleners-Smeets NW: Surgical excision versus Mohs" micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years" follow-up. Lancet Oncol 2008, 9(12): 1149 - 1156.

133. Pampena R, Palmieri T, Kyrgidis A, Ramundo D, Iotti C, Lallas A, Moscarella E, Borsari S, Argenziano G, Longo C: Orthovoltage radiotherapy for nonmelanoma skin cancer (NMSC): Comparison between 2 different schedules. J Am Acad Dermatol 2016, 74(2): 341 - 347.

134. Kwan W, Wilson D, Moravan V: Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004, 60(2): 406 - 411.

135. Balamucki CJ, Mancuso AA, Amdur RJ, Kirwan JM, Morris CG, Flowers FP, Stoer CB, Cognetta AB, Mendenhall WM: Skin carcinoma of the head and neck with perineural invasion. Am J Otolaryngol 2012, 33(4): 447 - 454.

136. Kropp L, Balamucki CJ, Morris CG, Kirwan J, Cognetta AB, Stoer CB, Mendenhall WM: Mohs resection and postoperative radiotherapy for head and neck cancers with incidental perineural invasion. Am J Otolaryngol 2013, 34(5): 373 - 377.

137. Mendenhall WM, Ferlito A, Takes RP, Bradford CR, Corry J, Fagan JJ, Rinaldo A, Strojan P, Rodrigo JP: Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol 2012, 48(10): 918 - 922.

138. Lin C, Tripcony L, Keller J, Poulsen M, Dickie G: Cutaneous carcinoma of the head and neck with clinical features of perineural infiltration treated with radiotherapy. Clin Oncol (R Coll Radiol) 2013, 25(6): 362 - 367.

139. Тимофеев ЛВ, Саакян СВ, Волошин СВ, Архипов АЮ: Аппликаторы для офтальмоонкологии. Стронций-90 + Иттрий-90. Москва; 2019.

140. Chopdar A: Carbon-dioxide laser treatment of eye lid lesions. Trans Ophthalmol Soc U K 1985, 104 (Pt 2): 176 - 180.

141. Вальский ВВ: Крупнофракционная брахитерапия злокачественных опухолей конъюнктивы. In: Достижения и перспективы офтальмоонкологии. edn. Москва; 2001: 98 - 100.

142. Бровкина АФ: Лучевая терапия в лечении опухолей органа зрения. Клин. офтальмология 2003, 4(1): 15 - 19.

143. Тимофеев ЛВ: Физические, технические, некоторые радиобиологические и медицинские аспекты контактной лучевой (бета-) терапии. Москва; 2016.

144. Тимофеев ЛВ: Расчетные методы дозиметрии бета-излучения. Москва: Типография "Вашформат"; 2017.

145. Laskar S, Gurram L, Laskar SG, Chaudhari S, Khanna N, Upreti R: Superficial ocular malignancies treated with strontium-90 brachytherapy: long term outcomes. J Contemp Brachytherapy 2015, 7(5): 369 - 373.

146. Lecuona K, Stannard C, Hart G, Rice J, Cook C, Wetter J, Duffield M: The treatment of carcinoma in situ and squamous cell carcinoma of the conjunctiva with fractionated strontium-90 radiation in a population with a high prevalence of HIV. Br J Ophthalmol 2015, 99(9): 1158 - 1161.

147. Stannard C, Sauerwein W, Maree G, Lecuona K: Radiotherapy for ocular tumours. Eye (Lond) 2013, 27(2): 119 - 127.

148. Khan MK, Powell S, Cox N, Robson A, Murrant N: Cervical in-transit metastasis from a truncal basal cell carcinoma. BMJ Case Rep 2010, 2010.

149. Kahveci OK, Okur E, Sahin O, Altuntas A, Okur N, Aktepe F: Metastatic basal cell carcinoma presenting as a neck mass. J Craniofac Surg 2010, 21(2): 592 - 594.

150. Dean NR, Sweeny L, Magnuson JS, Carroll WR, Robinson D, Desmond RA, Rosenthal EL: Outcomes of recurrent head and neck cutaneous squamous cell carcinoma. J Skin Cancer 2011, 2011: 972497.

151. Oddone N, Morgan GJ, Palme CE, Perera L, Shannon J, Wong E, Gebski V, Veness MJ: Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer 2009, 115(9): 1883 - 1891.

152. Coombs AC, Butler A, Allison R: Metastatic cutaneous squamous cell carcinoma of the parotid gland: prognostic factors. J Laryngol Otol 2018, 132(3): 264 - 269.

153. delCharco JO, Mendenhall WM, Parsons JT, Stringer SP, Cassisi NJ, Mendenhall NP: Carcinoma of the skin metastatic to the parotid area lymph nodes. Head Neck 1998, 20(5): 369 - 373.

154. Al-Othman MO, Mendenhall WM, Amdur RJ: Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage. Am J Otolaryngol 2001, 22(6): 387 - 390.

155. Taylor BW, Jr., Brant TA, Mendenhall NP, Mendenhall WM, Cassisi NJ, Stringer SP, Million RR: Carcinoma of the skin metastatic to parotid area lymph nodes. Head Neck 1991, 13(5): 427 - 433.

156. Veness M: Hypofractionated radiotherapy in older patients with non-melanoma skin cancer: Less is better. Australas J Dermatol 2018, 59(2): 124 - 127.

157. Zaorsky NG, Lee CT, Zhang E, Keith SW, Galloway TJ: Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis. Radiother Oncol 2017, 125(1): 13 - 20.

158. Xie P, Lefrancois P: Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. J Am Acad Dermatol 2018, 79(6): 1089 - 1100 e1017.

159. Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J: Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies. JAMA Dermatol 2016, 152(7): 816 - 824.

160. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA et al: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012, 366(23): 2171 - 2179.

161. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ: Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 2014, 70(1): 60 - 69.

162. Dreno B, Basset-Seguin N, Caro I, Yue H, Schadendorf D: Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist 2014, 19(8): 790 - 796.

163. Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dreno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L et al: Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 2015, 16(6): 729 - 736.

164. Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM et al: Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 2015, 72(6): 1021 - 1026 e1028.

165. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O et al: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer 2017, 17(1): 332.

166. Silver JK, Baima J: Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013, 92(8): 715 - 727.

167. Nilsson H, Angeras U, Bock D, Borjesson M, Onerup A, Fagevik Olsen M, Gellerstedt M, Haglind E, Angenete E: Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016, 6(1): e007997.

168. Siegel GW, Biermann JS, Chugh R, Jacobson JA, Lucas D, Feng M, Chang AC, Smith SR, Wong SL, Hasen J: The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework. J Multidiscip Healthc 2015, 8: 109 - 115.

169. Shehadeh A, El Dahleh M, Salem A, Sarhan Y, Sultan I, Henshaw RM, Aboulafia AJ: Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients" outcome. Hematol Oncol Stem Cell Ther 2013, 6(3 - 4): 105 - 111.

170. Cox CL, Montgomery M, Oeffinger KC, Leisenring W, Zeltzer L, Whitton JA, Mertens AC, Hudson MM, Robison LL: Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study. Cancer 2009, 115(3): 642 - 654.

171. Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, Committee EG: Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018, 29(Suppl 4): iv166 - iv191.

172. Committee. NMA: Topic: The Diagnosis and Treatment of Lymphedema. Position Statement of the National Lymphedema Network. In.; 2011: 1 - 19.

173. Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J: A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005 - 2017). PM R 2017, 9(9S2): S347 - S384.

174. Hu M, Lin W: Effects of exercise training on red blood cell production: implications for anemia. Acta Haematol 2012, 127(3): 156 - 164.

175. Bland KA, Zadravec K, Landry T, Weller S, Meyers L, Campbell KL: Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. Crit Rev Oncol Hematol 2019, 136: 79 - 85.

176. Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, Gollhofer A, Bloch W, Baumann FT: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014, 44(9): 1289 - 1304.

177. Lee JM, Look RM, Turner C, Gardiner SK, Wagie T, Douglas J, Sorenson L, Evans L, Kirchner S, Dashkoff C et al: Low-level laser therapy for chemotherapy-induced peripheral neuropathy. Journal of Clinical Oncology 2012, 30(15_suppl): 9019 - 9019.

178. Rick O, von Hehn U, Mikus E, Dertinger H, Geiger G: Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2017, 38(2): 85 - 94.

179. Kilinc M, Livanelioglu A, Yildirim SA, Tan E: Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014, 46(5): 454 - 460.

180. Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L: Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014, 9(9): e107418.

181. Westphal JG, Schulze PC: Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018, 10(Suppl 35): S4391 - S4399.

182. Ross M, Fischer-Cartlidge E: Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs 2017, 21(2): 226 - 233.

183. Kessels E, Husson O, van der Feltz-Cornelis CM: The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018, 14: 479 - 494.

184. Rief H, Omlor G, Akbar M, Welzel T, Bruckner T, Rieken S, Haefner MF, Schlampp I, Gioules A, Habermehl D et al: Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. BMC Cancer 2014, 14: 67.

185. Bensadoun RJ, Nair RG: Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy. Photomed Laser Surg 2015, 33(10): 487 - 491.

186. Temoshok L: Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology and tumor-host response. Soc Sci Med 1985, 20(8): 833 - 840.

187. Dirksen SR: Perceived well-being in malignant melanoma survivors. Oncol Nurs Forum 1989, 16(3): 353 - 358.

188. Lichtenthal WG, Cruess DG, Schuchter LM, Ming ME: Psychosocial factors related to the correspondence of recipient and provider perceptions of social support among patients diagnosed with or at risk for malignant melanoma. J Health Psychol 2003, 8(6): 705 - 719.

189. Sollner W, Zschocke I, Zingg-Schir M, Stein B, Rumpold G, Fritsch P, Augustin M: Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics 1999, 40(3): 239 - 250.

190. Devine D, Parker PA, Fouladi RT, Cohen L: The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 2003, 12(5): 453 - 462.

191. Folkman S, Lazarus RS, Gruen RJ, DeLongis A: Appraisal, coping, health status, and psychological symptoms. J Pers Soc Psychol 1986, 50(3): 571 - 579.

192. Беляев АМ, Чулкова ВА, Семиглазова ТЮ, Рогачев МВ (eds.): Онкопсихология для врачей-онкологов и медицинских психологов. Руководство. СПб: Любавич; 2017.

193. Fawzy FI, Cousins N, Fawzy NW, Kemeny ME, Elashoff R, Morton D: A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch Gen Psychiatry 1990, 47(8): 720 - 725.

194. Holland JC, Passik S, Kash KM, Russak SM, Gronert MK, Sison A, Lederberg M, Fox B, Baider L: The role of religious and spiritual beliefs in coping with malignant melanoma. Psychooncology 1999, 8(1): 14 - 26.

195. Baider L, Perry S, Sison A, Holland J, Uziely B, DeNour AK: The role of psychological variables in a group of melanoma patients. An Israeli sample. Psychosomatics 1997, 38(1): 45 - 53.

196. Lehto US, Ojanen M, Kellokumpu-Lehtinen P: Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol 2005, 16(5): 805 - 816.

197. Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL: Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993, 50(9): 681 - 689.

198. Fawzy FI, Kemeny ME, Fawzy NW, Elashoff R, Morton D, Cousins N, Fahey JL: A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch Gen Psychiatry 1990, 47(8): 729 - 735.

199. Fawzy FI, Canada AL, Fawzy NW: Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry 2003, 60(1): 100 - 103.

200. Boesen EH, Boesen SH, Frederiksen K, Ross L, Dahlstrom K, Schmidt G, Naested J, Krag C, Johansen C: Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2007, 25(36): 5698 - 5703.

201. Boesen EH, Ross L, Frederiksen K, Thomsen BL, Dahlstrom K, Schmidt G, Naested J, Krag C, Johansen C: Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2005, 23(6): 1270 - 1277.

202. McLoone J, Menzies S, Meiser B, Mann GJ, Kasparian NA: Psycho-educational interventions for melanoma survivors: a systematic review. Psychooncology 2013, 22(7): 1444 - 1456.

203. Sample A, He YY: Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 2018, 34(1): 13 - 24.

204. Craig S, Earnshaw CH, Viros A: Ultraviolet light and melanoma. J Pathol 2018, 244(5): 578 - 585.

205. Runger TM: Mechanisms of Melanoma Promotion by Ultraviolet Radiation. J Invest Dermatol 2016, 136(9): 1751 - 1752.

206. Green AC, Williams GM, Logan V, Strutton GM: Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011, 29(3): 257 - 263.

207. Ghiasvand R, Weiderpass E, Green AC, Lund E, Veierod MB: Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. J Clin Oncol 2016, 34(33): 3976 - 3983.

208. Marcil I, Stern RS: Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000, 136(12): 1524 - 1530.

209. Kiiski V, de Vries E, Flohil SC, Bijl MJ, Hofman A, Stricker BH, Nijsten T: Risk factors for single and multiple basal cell carcinomas. Arch Dermatol 2010, 146(8): 848 - 855.

210. Sanchez G, Nova J, Rodriguez-Hernandez AE, Medina RD, Solorzano-Restrepo C, Gonzalez J, Olmos M, Godfrey K, Arevalo-Rodriguez I: Sun protection for preventing basal cell and squamous cell skin cancers. Cochrane Database Syst Rev 2016, 7:CD011161.

211. Badertscher N, Meier M, Rosemann T, Braun R, Cozzio A, Tag B, Wensing M, Tandjung R: The role of skin self-examination at the Swiss skin cancer day. BMC Health Serv Res 2014, 14:581.

212. Wu S, Han J, Li WQ, Li T, Qureshi AA: Basal-cell carcinoma incidence and associated risk factors in U.S. women and men. Am J Epidemiol 2013, 178(6): 890 - 897.

213. Karagas MR, Stukel TA, Greenberg ER, Baron JA, Mott LA, Stern RS: Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992, 267(24): 3305 - 3310.

214. Ramachandran S, Rajaratnam R, Smith AG, Lear JT, Strange RC: Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. J Am Acad Dermatol 2009, 61(2): 247 - 251.

215. Flohil SC, Koljenovic S, de Haas ER, Overbeek LI, de Vries E, Nijsten T: Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands. Br J Dermatol 2011, 165(4): 874 - 881.

216. Flohil SC, van der Leest RJ, Arends LR, de Vries E, Nijsten T: Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer 2013, 49(10): 2365 - 2375.

217. Schneider J: The teaspoon rule of applying sunscreen. Arch Dermatol 2002, 138(6): 838 - 839.

218. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6): 649 - 655.